FDA PANEL OKs CERVICAL CANCER VACCINE

Published Online: Thursday, June 1, 2006

Merck's Gardasil, a vaccine that blocks viruses that cause most cervical cancers, has been given the green light by an FDA advisory committee. The panel voted 13 to 0, stating that the vaccine was safe and effective and should be approved.The FDA, which usually follows the panel's recommendation, is expected to make a decision this month.

The vaccine is indicated for the treatment of sexually transmitted diseases, particularly 4 strains of human papillomavirus that can cause cervical cancer and genital warts. A Merck official said that the vaccine could be recommended for women aged 9 to 26, but it would work best for individuals who have not yet had sex. The expected cost of the vaccine is $300 to $500 (for 3 injections given over 6 months).




Latest Articles
Pharmacists might be surprised to learn that Pinterest is a hotbed for anti-vaccine sentiment.
The FDA has approved betamethasone dipropionate spray, 0.05%, as a treatment for mild to moderate plaque psoriasis in patients aged 18 years and older.
Medication errors injure thousands of patients annually, and while mistakes occur with all medication classes, those involving antiretroviral therapies are particularly troublesome.
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Latest Issues
$auto_registration$
VSEO N/A